Expression of CD133 cancer stem cell marker in melanoma: a systematic review and meta-analysis

Zahra Madjd; Elham Erfani; Elmira Gheytanchi; Maziar Moradi-Lakeh; Ahmad Shariftabrizi; Mohsen Asadi-Lari

doi:10.5301/jbm.5000209

Back

Expression of CD133 cancer stem cell marker in melanoma: a systematic review and meta-analysis

Journal article

Open access

Peer reviewed

Expression of CD133 cancer stem cell marker in melanoma: a systematic review and meta-analysis

Zahra Madjd, Elham Erfani, Elmira Gheytanchi, Maziar Moradi-Lakeh, Ahmad Shariftabrizi and Mohsen Asadi-Lari

The International journal of biological markers, Vol.31(2), pp.e118-125

05/28/2016

DOI: 10.5301/jbm.5000209

PMID: 27102864

Files and links (1)

url

https://doi.org/10.5301/jbm.5000209View

Published (Version of record) Open Access

Abstract

CD133-positive melanoma cells are thought to be melanoma-initiating cells with cancer stem cell (CSC) characteristics. Some researchers have reported that CD133-negative subsets can also initiate tumors, so the clinical significance of a CD133-positive subpopulation of cells in melanoma remains controversial. This systematic review was designed to assess the value of CD133 as a CSC marker in melanomas. A meta-analysis was also performed to cumulatively analyze the data on CD133 expression levels in the selected studies. Eligible studies were identified via an electronic search through various databases including PubMed, MEDLINE, Ovid MEDLINE, and Web of Science (from May 2005 through September 2014) using the following keywords: "CD133 or prominin-1", "cancer stem cells", and "melanoma". Only articles in which CD133 antigen was detected by immunohistochemistry (IHC) were included. A meta-analysis was performed to identify any association between CD133 expression and clinical outcomes. Two hundred and ninety-nine melanoma cases from 5 studies were evaluated for expression levels of CD133 using IHC. Large heterogeneity was observed among the results (p<0.001, I2 = 94%). Approximately 47.9% (95% CI 23.7%-72.1%) of the studied melanoma cases had high CD133 expression. The I2 value and Q-test p value for heterogeneity were 89.0% and <0.001, respectively, and the pooled estimate of CD133 expression was 61.7% (95% CI 25.1%-98.4%). Our findings suggest that CD133 is not yet proven to be an appropriate biomarker in identifying CSCs of melanoma. Thus, detection of CD133 in combination with other putative CSC markers may be more valuable for clinical application.

AC133 Antigen - biosynthesis

AC133 Antigen - genetics

AC133 Antigen - metabolism

Animals

Humans

Immunohistochemistry

Melanoma - genetics

Melanoma - metabolism

Melanoma - pathology

Neoplastic Stem Cells - metabolism

Details

Title: Subtitle: Expression of CD133 cancer stem cell marker in melanoma: a systematic review and meta-analysis
Creators: Zahra Madjd - Iran University of Medical Sciences
Elham Erfani - Iran University of Medical Sciences
Elmira Gheytanchi - Iran University of Medical Sciences
Maziar Moradi-Lakeh - Iran University of Medical Sciences
Ahmad Shariftabrizi - University at Buffalo, State University of New York
Mohsen Asadi-Lari - Iran University of Medical Sciences
Resource Type: Journal article
Publication Details: The International journal of biological markers, Vol.31(2), pp.e118-125
DOI: 10.5301/jbm.5000209
PMID: 27102864
NLM abbreviation: Int J Biol Markers
ISSN: 1724-6008
eISSN: 1724-6008
Language: English
Date published: 05/28/2016
Academic Unit: Radiology
Record Identifier: 9984318820802771

Metrics

8 Record Views

33 Times Cited - Web of Science